TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Lindberg Life-Science AB
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
9
|
0 | |
| Financial expenses |
69
|
0 | |
| Earnings before taxes |
-216
|
9 | |
| EBITDA |
-124
|
-35 | |
| Total assets |
466
|
221 | |
| Current assets |
178
|
9 | |
| Current liabilities |
20
|
9 | |
| Equity capital |
446
|
212 | |
| - share capital |
50
|
50 | |
| Employees (average) |
1
|
0
|
0 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
95.7%
|
95.9% | |
| Turnover per employee | |||
| Profit as a percentage of turnover | -2400% | ||
| Return on assets (ROA) |
-31.5%
|
4.1% | |
| Current ratio |
890.0%
|
100% | |
| Return on equity (ROE) |
-48.4%
|
4.2% | |
| Change turnover |
9
|
0 | |
| Change turnover % | 11844% | ||
| Chg. No. of employees |
1
|
0
|
0 |
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.